- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | Curasight announces broadening and extension of patent protection for uTRACE | 1 | Cision News | ||
| CURASIGHT Aktie jetzt für 0€ handeln | |||||
| 03.09. | Transaction with shares in Curasight A/S made by managerial employee | 1 | Cision News | ||
| 28.08. | CURASIGHT: Half-year report Q2 2025 | 1 | Cision News | ||
| 26.08. | Curasight receives approval for brain cancer treatment trial | 1 | Investing.com | ||
| 26.08. | Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT in brain cancer patients | 216 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT belonging to Curasight's treatment platform.Initiation of the study marks a key... ► Artikel lesen | |
| 23.06. | Curasight A/S announces outcome of T03 warrant exercise | 2 | Cision News | ||
| 18.06. | Curasight A/S submits Clinical Trial Application for Phase 1 trial with uTREAT in brain cancer patients | 1 | Cision News | ||
| 13.06. | Spotlight Stock Market: Market Notice 110/25 - Last day of trading in Curasight A/S's subscription option CURAS TO 3 | 1 | Cision News | ||
| 03.06. | CURASIGHT: The exercise period commences for warrants of series TO3 on 4 June 2025 | 1 | Cision News | ||
| 02.06. | Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue | 1 | Cision News | ||
| 28.05. | CURASIGHT: Completed registration of rights issue | 1 | Cision News | ||
| 28.05. | Resolutions of the Annual General Meeting 2025 of Curasight A/S | 1 | Cision News | ||
| 21.05. | Curasight announces outcome in rights issue | 1 | Cision News | ||
| 15.05. | Subscription of new shares in the Right Issue 2025 exercised by Curasight management | 1 | Cision News | ||
| 13.05. | CURASIGHT: Notice of Annual General Meeting 2025 | 1 | Cision News | ||
| 13.05. | Last day of the subscription period in Curasight's rights issue of shares | 2 | Cision News | ||
| 07.05. | Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer | 2 | Cision News | ||
| 06.05. | Curasight's rights issue subscription period has commenced | 2 | Cision News | ||
| 02.05. | THE SUBSCRIPTION PERIOD IN CURASIGHT'S RIGHTS ISSUE OF SHARES BEGINS TODAY | 2 | Cision News | ||
| 30.04. | Curasight to present at HC Andersen Capital | 2 | Cision News |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 189,99 | +16,77 % | Praxis Precision Medicines prices $525M public offering | ||
| QIAGEN | 41,345 | +0,29 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| RANI THERAPEUTICS | 1,640 | +248,20 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| NUVALENT | 92,52 | +2,32 % | Stifel initiates coverage on Nuvalent stock with Buy rating | ||
| RECURSION PHARMACEUTICALS | 5,860 | -7,86 % | Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event | ||
| KYMERA THERAPEUTICS | 59,83 | -1,11 % | The Analyst Verdict: Kymera Therapeutics In The Eyes Of 6 Experts | ||
| IMMUNOVANT | 17,510 | +0,57 % | Truist Securities initiates Immunovant stock with Hold rating, $16 target | ||
| COGENT BIOSCIENCES | 16,390 | +0,18 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| TREVI THERAPEUTICS | 10,360 | -2,45 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 5,030 | -5,18 % | Sana Biotech surges as Eric Jackson calls it a 100-bagger | ||
| ARTIVA BIOTHERAPEUTICS | 6,020 | +118,12 % | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update | Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate... ► Artikel lesen | |
| IMMUNOME | 15,670 | -5,03 % | Where Immunome Stands With Analysts | ||
| ARVINAS | 9,520 | -1,60 % | Forecasting The Future: 7 Analyst Projections For Arvinas | ||
| AMYLYX PHARMACEUTICALS | 14,950 | -1,45 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
| DISC MEDICINE | 89,90 | +20,90 % | Disc Medicine Inc: Disc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP) | Disc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPPThe CNPV program is designed to reduce the drug application review process to 1-2 months WATERTOWN,... ► Artikel lesen |
CURASIGHT A/S gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURASIGHT A/S finden Sie auf Wallstreet Online.